{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004150","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.045827+00:00","generated_at":"2026-05-24T02:10:21.881428+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025","bullets":["Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).","Cash $14.8M at Dec 31, 2024; $4.8M capital raise and conversion of $19.5M debt to equity extend runway through Q1 2026.","Halneuron Phase 2b CINP trial dosing commenced; interim data readout expected Q4 2025.","Largest shareholder converted $19.5M loan to equity, strengthening balance sheet.","Exploring partnerships for IMC-2 (Long-COVID) and IMC-1 (fibromyalgia); update on IMC-1 expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004150","json":"https://secwatch.observer/filing/0001558370-25-004150.json","markdown":"https://secwatch.observer/filing/0001558370-25-004150.md","text":"https://secwatch.observer/filing/0001558370-25-004150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/0001558370-25-004150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/dwtx-20250331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:10:21.881428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}